OneSource Specialty Pharma Limited Q3 FY26 Concall Decoded: $400M FY28 Dream vs INR 290 Cr Reality – Approval Delays Just Ate $10M
1. Opening Hook
Nothing screams confidence like hosting an earnings call on a Saturday morning of a long weekend.
While most of us were planning brunch, management was explaining why revenues quietly slipped out the back door. The villain? Canadian semaglutide approvals playing hide-and-seek again.
Q3 FY26 wasn’t a disaster. It was a “transitory quarter.” Revenues deferred. MSAs paused. Capex accelerating. EBITDA compressing.
Yet, the FY28 $400 million revenue and $160 million EBITDA guidance remains untouched — almost like it’s laminated.
The elephant in the room wasn’t ignored. It was dissected. Canada, batch sizes, take-or-pay renegotiations, and a four-month plant shutdown all got airtime.
If this feels like the calm before either a breakout… or another delay, you’re not alone.
“FY26 is a transitory year.” (Translation: Don’t judge us by this year. Please. 😏)
“We remain extremely confident in achieving $400 million revenue and $160 million EBITDA by FY28.” (Translation: The target is sacred. Even if the path is foggy.)
“Revenue was deferred due to Canadian approval delays.” (Translation: It’s not lost. It’s… emotionally unavailable.)
“There is not one customer who has not revised forecasts upwards.” (Translation: Demand isn’t the problem. Paperwork is.)
“We chose not to take new MSAs to prioritize commercial capacity.” (Translation: Short-term revenue sacrificed for long-term margin dreams.)
“We are working with partners to increase batch sizes for better economics.” (Translation: Bigger batches, better margins, happier investors.)
“We have INR 250 crores of customer advances.” (Translation: Customers still believe. That’s comforting.)
“We softened take-or-pay clauses to build long-term partnerships.” (Translation: Relationships > short-term cash. Let’s hope that ages well.)
“H2 FY27 will mark material CSA revenues.” (Translation: The real story starts 18 months from now.)
4. Numbers Decoded
Metric
Q3 FY26
What It Really Means
Revenue
INR 2,903m
DDC missing in action
EBITDA
INR 173m
Fixed costs stayed loyal
Adj. PAT
–INR 472m
Accounting reality check
Inventory
Elevated
Launch-ready, regulator-not-ready
Capex Planned
INR 700 Cr+
Building ahead of approvals
Workforce Addition
+300 FTEs
Scaling before scaling
DDC absence = EBITDA compression. Inventory build = confidence in eventual launches. Capex intensity = management betting the house on semaglutide + biologics.
5. Analyst Questions
Q: Is INR 290 Cr a fair base revenue? Yes. That’s softgel + injectables steady state. DDC is the swing factor.
Q: What happens if approvals delay further? Inventory risk lies with customers. CDMO shield activated.
Q: Why renegotiate take-or-pay? To secure longer-term contracts beyond 3 years. Short-term flexibility for long-term lock-in.
Q: Peak DDC capacity utilization? 70–75% in commercial mode. MSAs are capacity underachievers.
Q: Oral GLP-1 threat? Will take max 25–30% innovator share. Generics? Not before 8–9 years.
